Opendata, web and dolomites

HOXA9 degradome SIGNED

Deciphering the machinery involved in stability of the transcription factor HOXA9.

Total Cost €


EC-Contrib. €






 HOXA9 degradome project word cloud

Explore the words cloud of the HOXA9 degradome project. It provides you a very rough idea of what is the project "HOXA9 degradome" about.

amenable    crispr    platform    therapeutic    leukemia    abundance    expression    performing    school    career    undoubtedly    machinery    flexible    clinical    outcome    cancer    levels    suitable    dkfz    50    critical    acquire    elucidate    screening    regulators    nodes    genes    druggable    usa    drive    hematopoiesis    plan    integrating    hits    aberrantly    elevated    aggressive    validate    skills    pharmaceutical    proteomics    alternative    transcription    tool    progression    screen    degradome    expressed    mutated    facs    heidelberg    controls    direct    followed    network    global    medical    interference    regulates    dissection    harvard    malignancy    patients    combat    assessing    strategy    inhibition    library    acute    myeloid    strategies    cas9    molecular    data    attractive    perturbation    pharmacologic    overcome    positive    employing    candidate    summary    specificity    protein    stability    poor    hoxa9    initiation    shows    degradation    regulatory    proteins    carcinogenesis    master    scientific    intensify    limitation    aml    milestone   

Project "HOXA9 degradome" data sheet

The following table provides information about the project.


Organization address
postcode: 69120

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website
 Total cost 239˙860 €
 EC max contribution 239˙860 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2016
 Duration (year-month-day) from 2016-11-07   to  2019-11-06


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Transcription factors are often mutated or aberrantly expressed in cancer and drive carcinogenesis. HOXA9 is a master transcription factor that controls a network of genes critical for hematopoiesis. It shows increased expression levels in more than 50% of patients with acute myeloid leukemia (AML), and is strongly associated with poor clinical outcome. Since the initiation and progression of AML depend on elevated HOXA9 levels, it represents an attractive therapeutic target to combat this aggressive malignancy. However, transcription factors are often not amenable to direct pharmacologic inhibition. To overcome this limitation, an alternative strategy aiming at interference with the transcription factor-specific 'degradome' - the degradation machinery regulates HOXA9 stability. To this end, we aim to elucidate the HOXA9 degradome with the goal of identifying its druggable nodes. Specifically, we plan to (1) identify regulatory proteins involved in the degradation of HOXA9 by performing a FACS-based positive selection screen with a focused CRISPR/Cas9 library as perturbation tool, (2) validate candidate proteins involved in the control of HOXA9 stability, and (3) characterize hits suitable for pharmacologic targeting. For the most promising HOXA9 regulators, we will determine their specificity by assessing global changes of protein abundance by proteomics. The potential of employing hits for pharmaceutical targeting will be evaluated by integrating molecular information with clinical data. In summary, this project aims to establish novel strategies for the dissection of the transcription factor HOXA9 degradome by developing a flexible screening platform. Through this project, I will not only acquire new skills but also establish a scientific network, which is expected to intensify the collaboration between DKFZ and Harvard Medical School. Two years’ experience in USA followed by one year in Heidelberg will be undoubtedly a milestone in my career development.


year authors and title journal last update
List of publications.
2018 Quinlan L. Sievers, Georg Petzold, Richard D. Bunker, Aline Renneville, Mikołaj Słabicki, Brian J. Liddicoat, Wassim Abdulrahman, Tarjei Mikkelsen, Benjamin L. Ebert, Nicolas H. Thomä
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
published pages: eaat0572, ISSN: 0036-8075, DOI: 10.1126/science.aat0572
Science 362/6414 2019-02-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HOXA9 DEGRADOME" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HOXA9 DEGRADOME" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MathematicsAnalogies (2019)

Mathematics Analogies

Read More